Quince Therapeutics names Leone Patterson audit, compensation committee chair in board overhaul
QNCX•Quince Therapeutics named Leone Patterson audit and compensation committee chair as part of a board overhaul. Three directors’ conditional resignations depend on shareholder approval of stock issuance tied to preferred-stock conversions and related warrants.
1. Board changes
Quince disclosed that directors June Bray, David Lamond and Christopher Senner conditionally agreed to resign two business days after the Oct. 6 meeting, contingent on shareholder approval of stock issuance tied to Series C Non-Voting Convertible Preferred Stock conversions and related warrants. The board is slated to add Catherine Bonuccelli, Leone Patterson, James Valentine and Drayton Wise; Patterson will chair the audit and compensation committees, and Valentine will chair governance.
